STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(ssets ...),Health

Date:11/2/2009

ssets $59,223 $52,582 ======= ======= Accounts payable $6,182 $6,626 Line of credit 2,220 2,200 Deferred income taxes - current 282 282 Obligations under capital leases - current 940 989 Other current liabilities 12,129 11,366 ------ ------ Total current liabilities 21,753 21,463 ------ ------ Notes payable - long-term, net of discount 4,389 4,414 Obligations under capital leases - long-term 1,084 1,335 Deferred income taxes - long-term 787 897 Other long-term liabilities 1,967 1,678 ----- ----- Total liabilities 29,980 29,787 Series A redeemable convertible preferred stock 6,780 6,768 Common stock 348 295 Additional paid-in capital 149,267 138,811 Accumulated other comprehensive income 3,456 2,812 Accumulated deficit (130,608) (125,891) -------- -------- Total stockholders' equity 22,463 16,027 ------ ------ Total liabilities, redeemable convertible preferred stock and stockholders' equity $59,223 $52,582
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery